Skip to main content
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRVI ISIN · US89532M1018 US Manufacturing
Open in API
Filings indexed 505 across all filing types
Latest filing 2020-06-15 Director's Dealing
Country US United States of America
Listing US TRVI

About Trevi Therapeutics, Inc.

https://www.trevitherapeutics.com/

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of its investigational therapy, Haduvio™ (oral nalbuphine ER). The company's primary program is aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions represent a significant unmet medical need with no approved therapies in the United States. Haduvio is a dual-mechanism therapy that acts as a kappa opioid receptor agonist and a mu opioid receptor antagonist, targeting both central and peripheral nerve pathways believed to cause chronic cough. The company has reported positive results from its Phase 2b CORAL trial in IPF chronic cough and its Phase 2a RIVER trial in refractory chronic cough.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-06-15 English
FORM 4 SUBMISSION
Director's Dealing
2020-06-15 English
FORM 4 SUBMISSION
Director's Dealing
2020-06-15 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It specifically states it is a "Definitive Additional Materials" filing related to the proxy statement for the 2020 Annual Meeting of Stockholders of Trevi Therapeutics, Inc. The content includes a notice of change of location for the annual meeting, details about voting procedures, and information about proposals to be voted on at the meeting. It does not contain the full proxy statement itself, nor does it include the actual annual report or financial statements. Instead, it supplements the proxy materials with updated logistical information. This type of document fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document is not an Annual Report (10-K), Earnings Release (ER), or Management Report (MDA), nor is it a simple announcement of a report publication (RPA). It is a definitive proxy solicitation material, thus best classified as PSI.
2020-05-29 English
10-Q
Interim / Quarterly Report Q1 2020
2020-05-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated May 7, 2020, from Trevi Therapeutics, Inc. It announces the company's financial results for the quarter ended March 31, 2020, and includes a press release as an exhibit. The text explicitly states that the information is furnished and not filed, and it is a current report rather than a full quarterly or annual report. The document is short (3731 characters) and primarily serves as an announcement of financial results rather than containing detailed financial statements or analysis. According to the definitions, an initial announcement of quarterly financial results is classified as an Earnings Release (ER).
2020-05-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.